Targeting of the programmed cell death protein (PD-1)/programmed death-ligand 1 (PD-L1) axis with checkpoint inhibitors has changed clinical practice in non-small cell lung cancer (NSCLC). However, clinical assessment remains complex and ambiguous. We aim to assess whether digital image analysis (DIA) and multiplex immunofluorescence can improve the accuracy of PD-L1 diagnostic testing. A clinical cohort of routine NSCLC patients reflex tested for PD-L1 (SP263) immunohistochemistry (IHC), was assessed using DIA. Samples of varying assessment difficulty were assessed by multiplex immunofluorescence. Sensitivity, specificity, and concordance was evaluated between manual diagnostic evaluation and DIA for chromogenic and multiplex IHC. PD-L1 ex...
Programmed cell death ligand 1 (PD-L1) immunohistochemistry is used to determine which patients with...
Programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) is accepted as a predictive biomarker f...
Therapeutic antibodies to programmed death receptor 1 (PD-1) and its ligand PD-L1 show promising cli...
Introduction The assessment of PD-L1 expression by immunohistochemistry is mandatory for the adminis...
Purpose Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved...
Purpose Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved...
AIMS: Investigate the impact of interlaboratory- and interobserver variability of immunohistochemist...
Purpose Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved...
Objectives: Immune checkpoint inhibitors have become integrated into the clinical management of non-...
Programmed death ligand-1 (PD-L1) expression as determined by immunohistochemistry (IHC) is potentia...
Background: Lung cancer is the most common cause of cancer-related death worldwide and unfortunately...
Assessment of programmed cell death ligand 1 (PD-L1) immunohistochemical staining is used for decisi...
Immune checkpoint inhibitors, including those concerning programmed cell death 1 (PD-1) and its liga...
AIMS: Immune checkpoint inhibitors have become a successful treatment in metastatic melanoma. The hi...
Treatment with pembrolizumab, an anti-programmed cell death-1 (PDCD-1) monoclonal antibody for the t...
Programmed cell death ligand 1 (PD-L1) immunohistochemistry is used to determine which patients with...
Programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) is accepted as a predictive biomarker f...
Therapeutic antibodies to programmed death receptor 1 (PD-1) and its ligand PD-L1 show promising cli...
Introduction The assessment of PD-L1 expression by immunohistochemistry is mandatory for the adminis...
Purpose Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved...
Purpose Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved...
AIMS: Investigate the impact of interlaboratory- and interobserver variability of immunohistochemist...
Purpose Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved...
Objectives: Immune checkpoint inhibitors have become integrated into the clinical management of non-...
Programmed death ligand-1 (PD-L1) expression as determined by immunohistochemistry (IHC) is potentia...
Background: Lung cancer is the most common cause of cancer-related death worldwide and unfortunately...
Assessment of programmed cell death ligand 1 (PD-L1) immunohistochemical staining is used for decisi...
Immune checkpoint inhibitors, including those concerning programmed cell death 1 (PD-1) and its liga...
AIMS: Immune checkpoint inhibitors have become a successful treatment in metastatic melanoma. The hi...
Treatment with pembrolizumab, an anti-programmed cell death-1 (PDCD-1) monoclonal antibody for the t...
Programmed cell death ligand 1 (PD-L1) immunohistochemistry is used to determine which patients with...
Programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) is accepted as a predictive biomarker f...
Therapeutic antibodies to programmed death receptor 1 (PD-1) and its ligand PD-L1 show promising cli...